Influence of tumor response on the survival of patients with extensive-stage small-cell lung cancer treated with the etoposide plus cisplatin chemotherapy regimen

Objective In this study, we evaluated the difference of progression-free survival(PFS) and overall survival(OS) between extensive-stage small-cell lung cancer(ES-SCLC) patients who acquired partial response(PR) or complete remission(CR) after two cycles of first-line chemotherapy with the etoposide plus cisplatin(EP) regimen and those who acquired PR or CR after four or six cycles.Methods A total of 106 eligible patients treated with the EP chemotherapy regimen for two to six cycles, at The General Hospital of Shenyang Military Region(China) between November 2004 and May 2011, were enrolled in this study. RECIST version 1.1 was used for the evaluation of chemotherapy efficiency. We followed up all eligible patients every 4 weeks. All statistical data were analyzed by using SPSS 21.0 statistical package for Windows.Results After a median follow-up of 293 days(range, 62–1531 days), all patients had died by the cutoff date. Fifty-one patients acquired PR or CR after two cycles of chemotherapy; the median PFS reached 6.0 months(95% CI, 5.1–6.9), and the median OS was 10.5 months(95% CI, 8.6–12.4). Twenty-eight patients acquired PR or CR after four or six cycles; the median PFS was 4.8 months(95% CI, 4.4–5.2), and the median OS was 7.5 months(95% CI, 6.8–8.2). Both PFS and OS showed a statistical difference between the two groups. Conclusion ES-SCLC patients who acquired PR or CR after two cycles of the EP regimen as first-line therapy had longer PFS and OS than those who acquired PR or CR after four or six cycles.

中医扶正在肿瘤防治中的作用与地位(英文)

Traditional Chinese medicine(TCM) treatment of cancer has a long history, and is an important part of cancer prevention and control in China. Fuzheng, also called reinforcing healthy qi and supplementing the root, is the most fundamental principle of TCM in cancer prevention and control. In recent decades, this treatment has been thoroughly studied and widely applied, and played a crucial role in cancer prevention and treatment. With regard to the treatment of malignant tumors, Chinese medicine is mainly used in the following areas: improving symptoms, enhancing the quality of life, reducing postoperative recurrence and metastasis, increasing efficacy and decreasing toxicity together with radiotherapy and chemotherapy treatments, and to some extent prolonging the survival of advanced tumors.

AEG1通过激活NF-κB和AP-1诱导肝癌HepG2细胞COX-2表达(英文)

Objective:The aim of this study was to investigate whether astrocyte elevated gene 1 (AEG1) regulates COX-2 expression in human hepatoma HepG2 cells and related pathways involved in this process. Methods:Human hepatoma HepG2 cells were transfected with pcDNA3.1(-)-AEG1 plasmid or psilencer2.0-AEG1-shRNA1 plasmid to up/down-regulate AEG1 expression, pcDNA3.1(-) and psilencer 2.0 empty vector plasmids were transfected respectively as control. Real-time RT-PCR was carried out to measure the expression levels of AEG1 and COX-2 mRNA. The expression levels of AEG1 and COX-2 protein were detected by Western blot. NF-κB signaling was blocked by PDTC, and AP-1 signaling was blocked by curcumin. Results:AEG1 mRNA and protein levels were increased after pcDNA3.1(-)-AEG1 transfection, and decreased after psilencer2.0-AEG1-shRNAs transfection. COX-2 mRNA and protein levels were increased in AEG1-overexpressing cells and decreased in AEG1-knockdown cells. Phosphorylations of p65 and c-jun were up-regulated in AEG1-overexpressing cells. Both PDTC and curcumin reduced COX-2 expression in HepG2 cells with AEG1 overexpression. Conclusion:AEG1-overexpressing and-knockdown HepG2 cells are established successfully. AEG1 could induce COX-2 expression though activating NF-κB and AP-1 in human hepatoma HepG2 cells.

P53基因可能成为三阴乳腺癌新的有效治疗靶点:一项Meta分析(英文)

Objective: The aim of this study was to explore the relationship between p53 gene and triple-negative breast cancer (TNBC), and determine that whether p53 gene could be a new effective therapeutic target. Methods: We identified studies with quantitative data on the relation of p53 gene and TNBC through searching 12 databases online (Oct. 1999-Oct. 2012) and reviewing the references, which were written in English or Chinese. Summary estimates of odds ratio (OR) was calculated using the fixed-effects model or the random-effects model as appropriate. Results: We identified 12 eligible studies with 1532 cases of TNBC patients and 6329 controls of non-TNBC patients. The test for homogeneity resulted in χ 2 = 200.16 (P < 0.05), it showed significant heterogeneity so that a random effect model was applied. Our results showed that the expression of p53 gene could be much stronger in TNBC group than that in non-TNBC group [OR = 2.10, 95% confidence interval (CI) = 1.21-3.65]. In ethnicity-subgroup analysis, we found that in Caucasian group, the expression of p53 gene were stronger in TNBC group (OR = 2.60, 95% CI = 1.21-5.57), but there was no statistical significance in Asian group (OR = 1.69, 95% CI = 0.83-3.45). Conclusion: P53 gene could be an effective predictor and a good therapeutic target for TNBC patients in the future, especially in Caucasian. Further researches focusing on p53 gene would gain a breakthrough in the treatment of TNBC.

一例伊朗男性汗管样小汗腺癌误诊为基底细胞癌病例报道(英文)

Syringoid carcinoma (syringoid eccrine carcinoma,or eccrine epithelioma) is a rare cutaneous tumor with some controversy regarding its correct definition.This tumor shows a slow growth and has often been for many years,some decades before diagnosis.It may also be difficult to differentiate from its benign counterpart (syringoma) or other adnexal carcinoma and cutaneous metastasis.There have been limited case reports of syringoid carcinoma in foreign literatures but none from Iran.Here we report a case of syringoid carcinoma in a 52 year-old Iranian man.Syringoid eccrine carcinoma is a very rare and uncommon diagnosed tumor thought to be derived from eccrine sweat apparatus.It locally invasive,destructive and often shows recurrence.It may also be difficult to differentiate from metastatic adenocarcinoma.

SPECT/CT同机融合显像和CT在估测口腔恶性肿瘤侵犯下颌骨范围的应用价值(英文)

Objective: The aim of our study was to compare the value of computed tomography (CT) and 99mTc-methylene-diphosphonate (MDP) SPECT (single photon emission computed tomography)/CT fusion imaging in determining the extent of mandibular invasion by malignant tumor of the oral cavity. Methods: This study had local ethical committee approval, and all patients gave written informed consent. Fifty-three patients were revealed mandibular invasion by malignant tumor of the oral cavity underwent CT and SPECT/CT. The patients were divided into two groups: group A (invasion-periphery-type) and group B (invasion-center-type). Two radiologists assessed the CT images and two nuclear medicine physicians separately assessed the SPECT/CT images in consensus and without knowledge of the results of other imaging tests. The extent of bone involvement suggested with an imaging modality was compared with pathological findings in the surgical specimen. Results: With pathological findings as the standard of reference, Group A: The extent of mandibular invasion by malignant tumor under-went SPECT/CT was 1.02 ± 0.20 cm larger than that underwent pathological findings. And the extent of mandibular invasion underwent CT was 1.42 ± 0.35 cm smaller than that underwent pathological examination. There were significant difference among the three methods (P < 0.01). Group B: The extent of mandibular invasion by malignant tumor underwent SPECT/CT was 1.3 ± 0.39 cm larger than that underwent pathological examination. The extent of mandibular invasion underwent CT was 2.55 ± 1.44 cm smaller than that underwent pathological findings. There were significant difference among the three methods (P < 0.01). The extent of mandibular invasion underwent SPECT/CT was the extent which surgeon must excise to get clear margins. Conclusion: SPECT/CT fusion imaging has significant clinical value in determining the extent of mandibular invasion by malignant tumor of oral cavity.

Cyclin E RNAi对乳腺癌细胞株生长抑制作用的实验研究(英文)

Objective:The aim of the study was to investigate the biological character change of breast cancer cell line by inhibiting the Cyclin E expressing level.Methods:Human breast cancer cell line MCF-7 was transfected by Cyclin E siRNA vector pEGFP/CCNE2.SiRNA-induced silencing of Cyclin E was determined at RNA level and protein level,respectively.The proliferation of MCF-7 and its sensitivity to chemical therapy were measured by CCK-8 assay,while cell cycle was measured by flow cytometry(FCM).Results:The plasmid could reduce the expression of Cyclin E.The proliferation ability of MCF-7 was decreased and the sensitivity to chemical therapy was enhanced according to the inhibition of Cyclin E expression.The transfected MCF-7 was arrested at G1 phase of cell cycle.Conclusion:The inhibition of Cyclin E can decrease the breast cancer cell's growth,increase its sensation to chemical therapy and slow down its cell cycle.The Cyclin E siRNA may provide us a practical tool for further study on the gene therapy to breast cancers.

Skp2与p27在大肠癌中的表达及临床病理关系的研究(英文)

Objective:The aim of this study was to study the expression and the clinical pathological relationship of p27 and Skp2 in the tissues of colorectal cancer,discuss the correlation between them.Methods:To determine the expressions of p27 and Skp2 among 30 cases of colorectal cancer tissue specimen and 18 cases of normal colorectal tissue samples with immunohistochemistry SP method.Results:The average positive rate of p27 among the normal colorectal tissue samples was 55.2%,which was obviously higher than that of colorectal cancer tissue samples(27.5%,P < 0.05).The correlation between the expression of p27 and the degree of differentiation of colorectal cancer;Dukes stage and lymph node metastasis were distinctly negative(P < 0.05).The average positive rate of Skp2 among the colorectal cancer tissue specimens was 9.5%,which was obviously higher than that of normal colorectal tissue samples(1.8%,P < 0.05).There was an obviously negative correlation between the expression of Skp2 and the degree of differentiation of colorectal cancer(P < 0.05),and the expression of Skp2 had no significant correlation with patients' age,sex,Dukes stage and lymph node metastasis(P > 0.05).There was an negative correlation between the expression of p27 and Skp2(r =-0.806,P < 0.01).Conclusion:The expression of Skp2 in the colorectal cancer tissues is correlative with the degradation of p27;Skp2,the oncogene of colorectal cancer,is involved in colorectal carcinogenesis,which may be the new target for the treatment of colorectal cancer.

吉非替尼对晚期非小细胞肺癌患者生活质量的改善(英文)

Objective:The aim of this study was to evaluate the effect of gefitinib on improvement of quality of life (QoL) of patients with advanced non-small cell lung cancer (NSCLC). Methods:There were 70 patients with advanced NSCLC. One oral gefitinib tablet (250 mg) was administered every day without interruption unless disease progression or unacceptable toxicity occurred. The impact of treatment on disease-related symptoms and QoL was evaluated with the Chinese versions of European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-LC13). Results: Fifty-eight patients had finished the questionnaires. The mean scores of five functioning scales (physical, role, emotional, cognitional and social) were 62.64, 56.03, 68.41, 64.67, 60.63 respectively after eight weeks of treatment, which were 52.30, 49.43, 64.39, 59.79, 52.30 respectively before treatment, and the mean score of global QoL after and before treatment was 60.17 and 52.70 respectively. There was statistical difference in five functioning scales and global QoL (P < 0.05). Mean scores of main general symptoms (fatigue and appetite loss) were 57.66 and 48.08 respectively after eight weeks of treatment, which were 61.11 and 51.72 respectively before treatment, and mean scores of disease-related symptoms (dyspnoea, coughing, empsyxis, pain in chest) were 48.66, 47.13, 26.82, 24.71 respectively after eight weeks of treatment, which were 54.98, 53.64, 27.78, 28.54 respectively before treatment. There was statistical difference in fatigue, dyspnoea, cough and pain in chest (P < 0.05). Response rate of five functioning and global QoL were all more than 50% after gefitinib treatment. Response rate of main general symptoms and disease-related symptoms were all more than 40%. QoL and symptom response correlated with disease control. The patients with better QoL had longer survival. Conclusion: gefitinib treatment can improve the QoL and symptoms of advanced NSCLC patients.

胃癌组织中微血管、微淋巴管生成和增殖细胞分布与胃癌预后的关系(英文)

Objective:We investigated the relationship between lymphangiogenesis,angiogenesis and cell proliferation in gastric cancer.Methods:We observed the central cancer tissues and the peritumoral tissues of 75 patients with gastric carcinoma by immunohistochemistry.Using D2-40,VEGFR-C and VEGFR-3 detected the microlymphatic density(MLD),CD34 and CD31 detected the microvessel density(MVD).The proliferation of the cells was labeled by Ki-67.Results:There were a few atresic streak lymphatic vessels in the central cancer tissues,but in the peritumoral tissues lymphatic increased and dilated,it appears adenoid structure.LMVD in the gastric central area(33.7 ± 14.7) decreased significantly than in the peripheral zone(61.8 ± 22.6;P < 0.01).The differences in the distribution and amount of microvessels were similar to lymphatic vessels.The central area of gastric cancer has a small amount of the distribution of focal Ki-67 positive tumor cells,while around the central area there were a large number of Ki-67 positive tumor cells,especially in one low power field(× 10).Gastric central area of the Ki-67 positive cells in gastric central area(49.5%) were significant decreasing than in the cancer peripheral zone(73.2%;P < 0.05).Conclusion:The mainly distribution of the neonatal lymphatic vessels,blood vessels and Ki-67 positive carcinoma in gastric cancer is anterior border of carcinoma tissues,especially in one low power field(× 10).The MLD,MVD and Ki-67 positive carcinoma might be an important index for the prognosis of gastric carcinoma.The more lymphatic microvessel,microvessel and Ki-67 positive carcinoma in the peritumoral tissues,the poorer prognosis,vice versa.

直肠癌五野调强放疗与传统适形放疗剂量学研究(英文)

Objective: The aim of the study was to compare the difference of dose distribution in clinical target volume and organ at risk (OAR) between five-field intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy (3DCRT) in the radiotherapy of rectal cancer. Methods: Fifteen patients with rectal cancer treated with radiotherapy (RT) were retrospectively analyzed. Among the patients, seven received RT preoperatively and 8 postoperatively. The target volume and the OARs such as the small bowel, bladder and femoral heads were contoured for each patient. 3DCRT-plan and IMRT-plan were performed for each patient respectively, with the prescribed dose covering at least 95% of the planning target volume (PTV). The conformity index (CI) and homogeneity index (HI) were used for evaluation of the dose distribution in the target volume, and the Dx% (the lowest dose to the x% volume of the OARs that received the highest dose of irradiation) and the mean dose were used for evaluation of the dose to OARs. Paired-T test was used for comparison of the difference between the two plans. Results: In the IMRT-plan and 3DCRT-plan, the CI were 0.94 and 0.87 (P = 0.000) and the HI were 1.13 and 1.17, respectively (P = 0.001). For small bowel, the D30%, D50% and the mean dose were 19.67 Gy, 15.13 Gy and 18.81 Gy in the IMRT-plan and 25.20 Gy, 22.20 Gy and 22.89 Gy in the 3DCRT-plan, respectively (P < 0.001 for all pairs of parameters). For bladder, the D30%, D50%, and the mean dose were 24.80 Gy, 34.20 Gy and 28.70 Gy in the IMRTplan, and 35.07 Gy, 44.67 Gy and 35.68 Gy in the 3DCRT-plan, respectively (P < 0.001 for all pairs of parameters). For femoral heads, the D5% in the IMRT-plan and 3DCRT-plan were 40.6 Gy and 40.47 Gy, respectively (P = 0.936), and the mean dose were 30.14 Gy and 25.57 Gy, respectively (P = 0.001). Conclusion: Five-field IMRT-plan is better than 3DCRT-plan in the conformity and the dose homogeneity within target volume and also better in sparing the small bowel and bladder.

原发性肝脏类癌的诊断一例报道(英文)

Primary hepatic carcinoid tumor (PHCT) is a extremely rare neoplasm, usually lacking specific symptoms. We present a histologically proved case and review the cases in the literature. The patient was an 65-year-old man with right upper abdominal pain and weight loss who underwent exploratory laparotomy for huge mass of the liver. Ultrasonography showed a well-demarked, cystic mass with irregular thick wall, whereas CT revealed a low-density tumor in nephrographic phase and peripheral enhanced areas in artery phase. He was diagnosed as PHCT by histological findings including positive staining of tumor cells for chromogranin A and synaptophysin, and no evidence of other primary source of tumor. Thus, a patient with this type of mass showed by imaging examination should be suspected of PHCT, for it is of great importance to clinical treatment.

HER1、HER2和HER3表达水平与IRESSA治疗晚期NSCLC疗效和预后的关系(英文)

Objective: Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently needed. Methods: We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinum- pretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate (RR), time to disease progression (TTP), and overall survival (OS). Results: A high expression (scores 2-3) of EGFR, HER2 and HER3 was verified in 16.7%, 43.3% and 21.1% of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR (35.9% vs. 15.7%, P = 0.027). The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients (53.8% vs. 22.1%, P = 0.036). EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion: The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy.

螺旋CT与超声造影在肾细胞癌诊断中的对比研究(英文)

Objective: To investigate the efficiency of helical CT comparing with contrast-enhanced ultrasound, and to im- prove the diagnosis efficiency of renal cell carcinoma (RCC). Methods: Thirty RCCs confirmed pathologically were studied retrospectively. The un-enhanced CT scan and the triphasic enhanced helical CT scan were performed in all cases, the gray-scale US and angiosonography with SonoVue were performed in all cases meantime. Results: 22 cases (73.3%) were diagnosed correctly by helical CT alone before operation. 7 cases (23.3%) were suspected as RCC with helical CT. One case (3.3%) was misdiagnosed with helical CT. 25 cases (83.3%) were diagnosed correctly with contrast-enhanced ultrasound alone pre-operation. One case (3.3%) was suspected as RCC with angiosonography. Four cases (13.3%) were misdiagnosed with angiosonography alone. 29 cases (96.7%) were diagnosed correctly by helical CT combining with angiosonography before operation, one case (3.3%) was diagnosed as renal mass with both helical CT and angiosonography. Conclusion: Contrast-enhanced ultrasound is sensitive in detecting blood flow, it can detect the enhancement of the tumor which cannot be detected by helical CT. CT and angiosonography have strong complement each other in the diagnosis of RCC.

吉西他滨耐药细胞系H460/Gem及其亲代细胞NCI-H460之间的不同(英文)

Objective: To discuss the difference between multi-drug resistant cell line H460/Gem and its parental cell NCI-H460 on the basis of establishment of human gemcitabine-resistant cell line H460/Gem so as to elaborate the possible mech-anisms of gemcitabine resistance. Methods: Human gemcitabine-resistant non-small cell lung cancer cell line H460/Gem was established by 2/3 clinical serous peak concentration gemcitabine intermittent selection from its parental cell human large cell lung carcinoma cell line NCI-H460 which was sensitive to gemcitabine. During the course of inducement, we had monitored their morphology, checked their resistance indexes and resistant pedigree by MTT method, gathered their growth curves and calculated their doubling time, examined their DNA contents and cell cycles by FCM; at the same time, we had measured its expressions of P53, EGFR, c-erb-B-2, PTEN, PCNA, c-myc, VEGF, MDR-1, Bcl-2, nm23, MMP-9, TIMP-1, CD44v6 proteins via immunocytochemistry staining, RRM1 and ERCC1 mRNA by real-time fluorescent quantitative-PCR. Results: The resis-tance index of H460/Gem' cells (the deputy of cells in the process of inducement) to gemcitabine was 1.201, and the cell line also exhibited cross-resistance to paclitaxol, fluorouraci, etoposide, cisplatin and oxaliplatin, but kept sensitivity to vinorelbine and taxotere. The doubling time of H460/Gem' cells was longer and figures in G0-G1 phase was decreased than that of NCI-H460 cells. Compared with NCI-H460 cells, H460/Gem' cells had achieved TIMP-1 protein expression emerged, nm23 protein expression enhanced, VEGF and MMP-9 protein expressions reduced, and CD44v6, P53 protein expressions van-ished, but expressions of EGFR, c-erb-B-2, PTEN, PCNA, c-myc, MDR-1, Bcl-2 proteins and RRM1, ERCC1 mRNA changed trivially. The resistance index of H460/Gem cells to gemcitabine was 1.644, and the cell line also exhibited cross-resistance to fluorouraci, cisplatin and oxaliplatin, but kept sensitivity to paclitaxol, vinorelbine, taxotere, and etoposide. The doubling time of H460/Gem cells was longer and figures in G0-G1 phase was decreased than those of NCI-H460 cells. The farther studies indicated that, compared with NCI-H460 cells, the expressions of MDR-1, nm23 and Bcl-2 proteins in H460/Gem cells had been enhanced, c-erb-B-2 protein expression emerged, P53, MMP-9 and VEGR protein expression had been weakened, but the changes of PTEN, PCNA, c-myc, TIMP-1, EGFR, CD44v6 protein, RRM1 mRNA and ERCC1 mRNA expressions were trivial. Furthermore, compared with its parental cells, H460/Gem cells were mixed with giant cells of different sizes that were larger and more irregular. Conclusion: The human gemcitabine-resistant non-small cell lung cancer cell line H460/Gem had achieved multi-drug resistance and great changes of biological characters compared with its parental cells. And these changes possibly participated in the formation of multidrug resistance.

低氧对人肺腺癌A549细胞迁移和黏附的影响(英文)

Objective: To evaluate the effect of hypoxia on migration, invasion and adhesion to endothelium of human pulmonary adenocarcinoma A549 cells. Methods: Wound-healing and Transwell invasion assays were performed to study the effect of hypoxia on migration and invasion of A549 cells, and A549 cells were added to a monolayer of human umbilical vein endothelial cells (HUVECs) to test the ability to adhere to endothelium. Immunofluorescence assay and luciferase reporter gene assay were also used to evaluate the effect of hypoxia on distribution of E-cadherin, β-catenin, and actin, and hypoxia-inducible factor-1 (HIF-1)-dependent transcription, respectively. Results: Hypoxia facilitated A549 cell migration, invasion, and A549 cell-endothelial cells adhesion, and modulated the distribution of E-cadherin and β-catenin, and actin cytoskeleton rearrangement, and up-regulated HIF-1-dependent reporter gene expression in A549 cells. Conclusion: Promotion of A549 cell migration, invasion, and adhesion on endothelium by hypoxia might be modulated through its up-regulating HIF-1-dependent gene expression, which then induced the redistribution of E-cadherin and β-catenin, and the actin cytoskeletal reorganization.

金克诱导Molt-4细胞凋亡及其机制研究(英文)

Objective: To investigate the apoptosis-inducing effect of Jinke on Molt-4 cells and its possible mechanism. Methods: The Molt-4 cells were treated with different concentrations of Jinke and then cultured for necessary time. The An- nexin-V / PI method was used to detect the apoptosis rate. The cell cycle was analyzed by DNA content with flow cytometry. Double parameters analysis of cyclins / DNA was performed to detect the expression of cyclin E. API method was used to confirm the cell cycle-specific apoptosis. The expressions of Bcl-2 and Bax were detected by western blot. Results: 24 h after the treatment of 0.5, 1.0, 1.5, 2.0 and 3.0 mg/mL Jinke, the apoptosis rate of Molt-4 cells was evaluated in a concentra- tion-dependent manner, from 5.2% of the control group to 41.0% of the 3.0 mg/mL Jinke group. When the Molt-4 cells were cultured with 1.5 mg/mL Jinke, the apoptosis rate was evaluated in a time-dependent manner. DNA content analysis showed that G0/G1 phase of Molt-4 cells increased in a time-dependent manner. The expression of cyclin E increased gradually. API assay showed the apoptosis cells were almost in G0/G1 phase. Western blot showed the Bcl-2 was down-regulated and the Bax was up-regulated. Conclusion: Jinke could induce G1 phase-specific apoptosis in Molt-4 cells in time- and concentra- tion-dependent manners involving G1 phase arrest. The mechanism of apoptosis inducing effect may be related to the up- regulation of Bax and the down-regulation of Bcl-2.

Chinese-German Journal of Clinical Oncology

1. Arms and scope Chinese-German Journal of Clinical Oncology is an international professional academic periodical on oncology, being co-edited by China and Germany. The Journal, with the authors from

垂体泌乳素腺瘤中雌激素、雄激素的表达与临床特点的相关性研究

目的研究雌激素(ER)和雄激素(AR)受体与泌乳素腺瘤临床表现之间的相关关系,探讨泌乳素腺瘤发病机理中ER和AR表达可能存在的性别差异。方法搜集同济医院2000年12月～2001年12月期间经蝶窦手术的30例泌乳素腺瘤病例,实验分为两部分。第一部分：回顾性分析了病人性别、年龄、血浆泌乳素水平、肿瘤的大小、侵袭性、CT和MRI以及手术发现、术前使用溴隐亭情况和肿瘤复发等临床资料,第二部分：选取30例中的20例泌乳素腺瘤标本,用免疫组化技术检测了ER和AR的表达。运用卡方检测行统计学分析泌乳素腺瘤的各种临床特点和ER、AR表达间的关系。结果统计分析结果显示ER和AR的表达与泌乳素腺瘤的特征如：性别、年龄、肿瘤体积、肿瘤的侵袭性无关(P＞0.05)。结论泌乳素腺瘤的性别、年龄、肿瘤体积、肿瘤的侵袭性程度不会影响ER和AR的表达。男性泌乳素腺瘤较女性患者更具侵袭性。单纯手术治疗巨大腺瘤或血浆泌乳素＞200ng／mL的肿瘤疗效并不理想。手术后溴隐亭治疗的应用与患者的性别无关,但与手术前肿瘤的体积和泌乳素水平相关。

病理学切缘和以p53与eIF4E为指标的分子切缘预测喉癌患者预后(英文)

目的探讨病理学切缘和以p53、eIF4E为指标的分子切缘在预测喉癌患者预后中的价值。方法选择了253例喉癌患者进行病理学切缘研究，在以上病理学阴性切缘中选择67例，应用免疫组化方法检测p53、eIF4E蛋白的表达以进行分子切缘研究。结果1．病理学切缘、p53切缘、eIF4E切缘的阳性率分别是20．2％，19．4％和32．8％；2．阳性切缘患者的复发率高于切缘阴性者，包括病理学切缘(70．6％vs35．1％，P=0．0000)、p53切缘(69．2％vs33．3％，P=0．018)、eIF4E切缘(63．6％vs28．90A，P=0．018)；而切缘阳性者5年累积生存率低于切缘阴性者，包括病理学切缘(37．52％vs64．37％，P=0．0023)、p53切缘(24．62％vs75．69％，P=0．0012)、eIF4E切缘(43．31％vs77．52％，P=0．0006)。结论病理学切缘和以p53、eIF4E为指标的分子切缘阳性者的预后比切缘阴性者差，而p53和eIF4E可以从病理学切缘阴性者中发现预后更差的患者，并且eIF4E可能是优p53的分子指标。